New Cancer Test May Identify Who Won't Respond to Chemotherapy: Study Suggests
Advertisement
A new study, published in Nature Genetics, introduced biomarkers that can predict resistance to widely used chemotherapy drugs, potentially benefiting hundreds of thousands of cancer patients annually.
Researchers developed a genomic test that identifies patients unlikely to respond to platinum-, taxane-, or anthracycline-based chemotherapies.
The method relies on identifying biomarkers linked to chromosomal instability—genetic changes in tumor cells caused by abnormal chromosome numbers. These variations form distinctive patterns unique to each tumor. The study demonstrated how these patterns can predict treatment resistance before chemotherapy begins.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.